Difference between revisions of "Volasertib (BI-6727)"
Jump to navigation
Jump to search
m |
|||
Line 9: | Line 9: | ||
*4/14/2014: Granted FDA orphan drug status for treatment of [[Acute myeloid leukemia | acute myeloid leukemia]]. | *4/14/2014: Granted FDA orphan drug status for treatment of [[Acute myeloid leukemia | acute myeloid leukemia]]. | ||
− | [[Category: | + | [[Category:Drug index]] |
+ | [[Category:Chemotherapy]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
Line 15: | Line 16: | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
+ | |||
+ | [[Category:Orphan drug]] |
Revision as of 05:12, 23 November 2014
Mechanism of action
Polo-like kinase 1 (PLK1) inhibitor
Preliminary data
Acute myeloid leukemia
- Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood. 2014 Aug 28;124(9):1426-33. Epub 2014 Jul 8. link to original article PubMed
History of changes in FDA indication
- 4/14/2014: Granted FDA orphan drug status for treatment of acute myeloid leukemia.